. Formononetin does not affect expression of MMP9 /MMP2 and cell migration. (A) EAHY-926 cells were treated with formononetin overnight at the indicated concentrations. After treatment, total RNA was extracted, and expression of MMP9 and MMP2 were determined by q-QT-PCR, n=5. (B) After scratch, EAHY-926 cells were incubated in presence or absence of formononetin for 24 h, and migration rate was evaluated, n=5. Data are presented as mean ± SEM, ns: not significantly different.
Figure S2. Formononetin decreases the cell apoptosis in lesion plaque and in vitro.
(A) Apoptosis in lesion areas of the mice used in Figure 1A by TUNEL staining, n=5. (B) After treatment of ox-LDL (100 g mL-1) and formononetin (5 M), macrophages were incubated with FITC Annexin V in buffer containing propidium iodide (PI) and analyzed by flow cytometry. Cells undergoing apoptosis were FITC Annexin V positive and PI negative, n=5. Data are presented as mean ± SEM, *P<0.05, significantly different as indicated. Figure S3 . Inhibition of SRA-mediated ox-LDL endocytosis by formononetin may be dynamin-mediated. (A) Peritoneal macrophages (PMs) were incubated with dynamin inhibitor dynasore (Dyn, 1M) in presence or absence of formononetin (FNT, 5 M), simultaneously with DiI-oxLDL (10 g/mL), and then, ability of cellular uptake was assessed, n=5. Data are presented as mean ± SEM, *P<0.05, significantly different as indicated; ns, not significantly. Figure 1 were performed immunofluorescent staining with anti-Asialo GM1, CD4, CD22, 33D1, Mast Cell Chymase antibodies with quantitative analysis of MFI (mean fluorescent intensity), n=5. Data are presented as mean ± SEM, *P<0.05 versus Ctrl group, ns: not significantly different.
